Background The prevalence of the common cold in children
T he common cold is a self-limiting acute, upper respiratory tract infection often with flu-like symptoms including acute cough, rhinovirus). 1 2 Children suffer from the common cold an average of 6-8 times per year and coughing is a frequent complaint by parents who take their child to visit the doctor.
due to the common cold, which makes it one of the prevalence of the common cold in children below shown that erdosteine increases mucociliary clearadhesion. [5] [6] [7] [8] [9] One study reported that in 158 children aged 2-12 years old with acute lower respiratory tract From the Department of Child Health, Gadjah Mada University Medical Reprint request to hu.yenny@yahoo.com of the erdosteine group by the 5th day of therapy, respiratory tract infection showed statistically significant improvement in symptoms in 59.8% in the erdosteine group after 7 days of the therapy compared 11 Erdosteine is widely prescribed by physicians. However, there is little data on its effectiveness in acute upper respiratory tract infections, especially common colds in children. Therefore, this study aims to assess the effectiveness of erdosteine on clinical improvement of acute cough symptoms in children
Methods
We performed a randomized, double-blind, con- Table 1) , good nutritional state, and who antihistamines or corticosteroid therapy before the media, heart disease, cough preceded by choking, lower respiratory tract symptoms (tachypnea, dyspnea, rhonchi, wheezing, stridor, crepitation, asymmetric breathing sounds, or chest wall retractions), and Subjects fulfilling the criteria were computer randomized into 2 groups after determining the sample or placebo dry syrup in 2 divided doses daily for 6 days. syrup, another dose was given. Erdosteine and placebo preparations were stable up to 7 days and similar in package, flavor and color.
Disease duration was measured starting from study. Risk factors were defined as a history of common as cigarette smoke or mosquito repellant during the subject had fever. School was defined as children's enrollment status in kindergarten. Mother's education is shown as the level completed. defined as a decrease in the total clinical cough score, while no improvement was a persistence or increase in the total cough score ( Table 1) .
drug effects were taken as secondary outcomes.
effects related to the drug during the treatment. Drug compliance was defined as fulfilling the drug administration schedule and no missed dosages during the entire treatment course. Compliance was been taken by the patients. Dropout was defined as the parents' refusal to continue the study, inability to reestablish contact with parents, or the child's condition worsening and requiring hospitalization.
diagnosed with the common cold who met the inclusion criteria through history taking and physical parents how to fill the drug compliance forms, and set Effectiveness of the erdosteine compared to placebo was predicted to be 25%, based on data obtained from previous studies on acute cough.
Data was presented in tabulation form with means and standard deviations. Numerical data was then grouped into categories and converted to percentages. Chi square test was used to assess differences between erdosteine and placebo in acute cough improvement. Multivariate logistic regression was used to assess and identify other factors influencing cough improvement. Subjects who dropped out or were lost on follow up were included, since this was an intention to treat analysis. We used a confidence interval of 95% and performed doubled data entry and statistical analysis Results placebo group. One participant in the placebo group dropped out because they were unable to be contacted (Figure 1) . We did an intention to treat analysis and therefore included subject who dropped out.
Demographic characteristics of participants are shown in Table 2 . There were no significant differences in subjects' age, weight, gender, duration of the disease, initial cough score, mothers' education, treatment and placebo groups. Before treatment, cough severity of total score 2-3 was not significantly
On the 6 th day of follow-up, no significant difference in clinical improvement of cough symptoms between the two groups was observed. In the erdosteine group, 92.9% improved and in the placebo Table 3 ). During the course of treatment, no side effects were reported who suffered from vomiting but did not require hospitalization. In our study, there was a significant difference among children that attended kindergarten between variate regression analysis, we found that children attending kindergarten did not strongly correlate to treatment between the groups (Table 4) .
By the 3rd day of treatment, there was improand in the placebo group (98.6%), however they were not significantly different. (Figure 2) 
Discussion
Our findings differed from those of two previous studies by Titti et al. , and Balli et al. 11 be that their studies were on subjects with acute lower respiratory tract infections, which are more likely to be caused by bacteria. For their purposes, erdosteine was prescribed along with antibiotics. The anti-adhesive effect of erdosteine prevents bacterial adhesion to the respiratory tract and synergizes with the antibiotic effects, influencing outcomes. 13 in the nature of cough receptors in the upper and lower respiratory tracts. The upper tract is mechanosensitive, while lower tract is chemosensitive. In vitro studies showed no correlation between concentrations of cold patients, while IL-8 levels significantly increased in symptomatic patients. 15, 16 Erdosteine significantly reduced the production of tumor necrosis factor-(TNF-) and interleukin-1 ,6 (IL-1 ,6) in alveolar macrophages. 17, 18 Children under five years of age who attended higher chance of having a common cold compared to those staying at home. 19 We found a significant difference among children attending kindergarten between the erdosteine and placebo groups. Systematic review studies show that cough medicine is not recommended as first-line therapy for acute cough in children.
When used, patients require routine monitoring and the drug must be discontinued period. 23 of cough medicines to parents and encourage them to bring their children back if coughing does not subside to look for possible alternative causes. Table 3 . Improvement of acute cough symptoms. some subjectivity to the quantitative scoring of cough severity. Total cough scores were measured at home by parents and there was no kappa test for agreement between parents and doctors in assessing coughs.
In conclusion, we observed that erdosteine had no effect on clinical improvement of cough symptoms in upper respiratory tract illnesses compared to the placebo. This study may form the basis for future research.
